US 11,707,409 B2
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
Wendell Porter Weeks, Corning, NY (US); Robert Anthony Schaut, Painted Post, NY (US); Steven Edward DeMartino, Painted Post, NY (US); and John Stephen Peanasky, Big Flats, NY (US)
Assigned to CORNING INCORPORATED, Corning, NY (US)
Filed by Corning Incorporated, Corning, NY (US)
Filed on Oct. 25, 2012, as Appl. No. 13/660,704.
Claims priority of provisional application 61/656,998, filed on Jun. 7, 2012.
Claims priority of provisional application 61/551,163, filed on Oct. 25, 2011.
Prior Publication US 2013/0202823 A1, Aug. 8, 2013
Int. Cl. A61J 1/14 (2023.01); A61J 1/00 (2023.01); A61K 39/395 (2006.01); C03C 3/087 (2006.01); C03C 3/091 (2006.01); C03C 21/00 (2006.01); C03C 4/20 (2006.01); A61J 1/06 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/28 (2006.01); A61K 31/403 (2006.01); A61K 38/18 (2006.01); C07K 16/24 (2006.01)
CPC A61J 1/1468 (2015.05) [A61J 1/00 (2013.01); A61J 1/065 (2013.01); A61K 31/403 (2013.01); A61K 38/17 (2013.01); A61K 38/1816 (2013.01); A61K 38/193 (2013.01); A61K 38/28 (2013.01); A61K 39/3955 (2013.01); C03C 3/087 (2013.01); C03C 3/091 (2013.01); C03C 4/20 (2013.01); C03C 21/002 (2013.01); C07K 16/241 (2013.01); Y02A 50/30 (2018.01); Y10T 428/131 (2015.01)] 58 Claims
OG exemplary drawing
 
1. A delamination resistant pharmaceutical container comprising a pharmaceutical composition stored within the container, wherein the pharmaceutical container comprises a glass composition comprising:
SiO2 in a concentration greater than 74 mol. %;
ZrO2 in a concentration less than 1 mol. %;
alkaline earth oxide comprising MgO and CaO, wherein CaO is present in an amount greater than or equal to 0.1 mol. % and less than or equal to 1.0 mol. % relative to the glass composition, and a ratio (CaO (mol. %)/(CaO (mol. %)+MgO (mol. %))) is less than or equal to 0.5; and
Y mol. % alkali oxide, wherein the alkali oxide comprises Na2O in an amount greater than 8 mol. %,
wherein the glass composition is free of boron and compounds of boron,
wherein the pharmaceutical composition comprises one of rituximab, bevacizumab, ranibizumab, trastuzumab, an antibody, or an antigen binding fragment thereof, that binds CD20, an antibody, or an antigen binding fragment thereof, that binds vascular endothelial growth factor (VEGF), an antibody, or an antigen binding fragment thereof, that binds vascular endothelial growth factor-A, or an antibody, or an antigen binding fragment thereof, that binds HER2.